Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | AHCY | P23526 | 9/20 | 0.48 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780483 | 0.89 | AHCY (0.49) | ADORA3AHCYDOT1LPRMT5WDR77 | |
| SCHEMBL536759 | 0.89 | AHCY (0.52) | ADORA3AHCYDOT1LHIF1ATMEM97 | |
| SCHEMBL3486341 | 0.87 | AHCY (0.60) | AHCYDOT1LHIF1ATMEM97SIGMAR1 | |
| SCHEMBL8362057 | 0.86 | ADORA3 (0.50) | ADORA3AHCYDOT1LHIF1ATMEM97 | |
| SCHEMBL6421905 | 0.83 | ADORA3 (0.58) | ADORA3AHCY | |
| SCHEMBL1563449 | 0.82 | ADORA3 (0.54) | ADORA3AHCY | |
| SCHEMBL3292851 | 0.79 | AHCY (0.52) | AHCYDOT1LPRMT5WDR77HIF1A | |
| SCHEMBL6692383 | 0.78 | AHCY (0.54) | ADORA3AHCYDOT1LHIF1ATMEM97 | |
| SCHEMBL1972796 | 0.77 | AHCY (0.63) | ADORA3AHCYDOT1LPRMT5WDR77 | |
| SCHEMBL8664327 | 0.77 | ADORA1 (0.58) | ADORA3AHCYDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518957-B2 | Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120264769-A1 | METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF | The United States of Americia, as represented by the Secretary, Department of Health and Human Serv (US) | 2012-10-18 | — | — | US | disclosed |
| US-8071601-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2011-12-06 | — | — | US | disclosed |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-7799922-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2010-09-21 | — | — | US | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7709489-B2 | Imidazoquinoline derivatives as adenosine A3 receptor ligands | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | US | disclosed |
| US-7547696-B2 | Such as 4-methoxy-N-[6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl]-benzamide; improved solubility | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| WO-2007089617-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH | COMBINATORX, INCORPORATED (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007056457-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1560828-B9 | IMIDAZOQUINOLINE DERIVATIVES AS ADENOSINE A3 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2007-02-14 | — | — | EP | disclosed |
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS U.S. LLC (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1663982-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2006-06-07 | — | — | EP | disclosed |
| EP-1560828-B1 | IMIDAZOQUINOLINE DERIVATIVES AS ADENOSINE A3 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2006-05-03 | — | — | EP | disclosed |
| US-20050234056-A1 | Imidazoquinoline derivatives as adenosine A3 receptor ligands | SANOFI-AVENTIS (FR) | 2005-10-20 | — | — | US | disclosed |
| EP-1560828-A1 | IMIDAZOQUINOLINE DERIVATIVES AS ADENOSINE A3 RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2005-08-10 | — | — | EP | disclosed |
| WO-2005009969-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004046146-A1 | IMIDAZOQUINOLINE DERIVATIVES AS ADENOSINE A3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885AHCY 3011/4885DOT1L 3576/4885 |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885AHCY 3011/4885DOT1L 3576/4885 |
| US-20050234056-A1 | Imidazoquinoline derivatives as adenosine A3 receptor ligands | ADORA3, ADORA1, ADORA2A | ADORA3 1/4885AHCY 2221/4885DOT1L 2245/4885 |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | ADORA3 1/4885AHCY 1295/4885DOT1L 4000/4885 |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | ADORA3 1/4885AHCY 1320/4885DOT1L 3620/4885 |
| US-20120264769-A1 | METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885AHCY 448/4885DOT1L 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.